NEXGEL Announces $2,000,000 Registered Direct Offering
November 11, 2024 17:35 ET
|
NEXGEL, INC.
LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle,...
NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
August 12, 2024 09:15 ET
|
NEXGEL, INC.
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading...
NEXGEL Announces $1,110,000 Registered Direct Offering Led by Insiders
August 12, 2024 09:00 ET
|
NEXGEL, INC.
LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle,...
NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively
July 08, 2024 16:05 ET
|
NEXGEL, INC.
LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle,...
NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America
June 11, 2024 08:40 ET
|
NEXGEL, INC.
LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle,...